These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37873674)

  • 41. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.
    von Pawel J; Jotte R; Spigel DR; O'Brien ME; Socinski MA; Mezger J; Steins M; Bosquée L; Bubis J; Nackaerts K; Trigo JM; Clingan P; Schütte W; Lorigan P; Reck M; Domine M; Shepherd FA; Li S; Renschler MF
    J Clin Oncol; 2014 Dec; 32(35):4012-9. PubMed ID: 25385727
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and efficacy of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy for small-cell lung cancer: a retrospective, cohort-controlled trial.
    Wang C; Zhu S; Miao C; Wang Y; Chen J; Yuan S; Hu X
    BMC Cancer; 2022 May; 22(1):542. PubMed ID: 35562713
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A randomized phase III study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer.
    Sekine I; Okamoto H; Horai T; Nakagawa K; Ohmatsu H; Yokoyama A; Katakami N; Shibuya M; Saijo N; Fukuoka M
    Clin Lung Cancer; 2014 Mar; 15(2):96-102. PubMed ID: 24361248
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The efficacy of amrubicin on central nervous system metastases originating from small-cell lung cancer: a case series of eight patients.
    Miura S; Kaira K; Kaira R; Akamatsu H; Ono A; Shukuya T; Tsuya A; Nakamura Y; Kenmotsu H; Naito T; Murakami H; Takahashi T; Endo M; Yamamoto N
    Invest New Drugs; 2015 Jun; 33(3):755-60. PubMed ID: 25846908
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The safety and efficacy of amrubicin in the treatment of previously untreated extensive-disease small-cell lung cancer: a meta-analysis.
    Wu JF; Zhou JJ; Li XA; Hu LH; Wen ML
    Onco Targets Ther; 2019; 12():5135-5142. PubMed ID: 31303766
    [No Abstract]   [Full Text] [Related]  

  • 46. A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer.
    Kaira K; Sunaga N; Tomizawa Y; Yanagitani N; Shimizu K; Imai H; Utsugi M; Iwasaki Y; Iijima H; Tsurumaki H; Yoshii A; Fueki N; Hisada T; Ishizuka T; Saito R; Mori M
    Lung Cancer; 2010 Jul; 69(1):99-104. PubMed ID: 19853960
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis.
    Song Z; Shao L; Lin B; Zhang Y
    Clin Transl Oncol; 2013 Oct; 15(10):843-8. PubMed ID: 23423808
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of nab-paclitaxel plus PD-1/PD-L1 inhibitor on chemorefractory relapsed small-cell lung cancer.
    Mu F; Fan B; Li H; Qin W; Wang C; Zou B; Wang L
    Future Oncol; 2023 Jun; 19(19):1367-1378. PubMed ID: 37114967
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
    Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
    Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Second-line chemotherapy and its survival analysis of 181 patients with extensive-stage small cell lung cancer in a single institute].
    Ma M; Wang M; Xu Y; Hu K; Liu H; Li L; Zhong W; Zhang L; Zhao J; Wang H
    Zhongguo Fei Ai Za Zhi; 2013 Nov; 16(11):572-8. PubMed ID: 24229622
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase II study of amrubicin at a dose of 45 mg/m2 in patients with previously treated small-cell lung cancer.
    Asao T; Nokihara H; Yoh K; Niho S; Goto K; Ohmatsu H; Kubota K; Yamamoto N; Sekine I; Kunitoh H; Fujiwara Y; Ohe Y
    Jpn J Clin Oncol; 2015 Oct; 45(10):941-6. PubMed ID: 26232449
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Retrospective analysis of efficacy and safety of amrubicin in refractory and relapsed small-cell lung cancer.
    Shimokawa T; Shibuya M; Kitamura K; Hosomi Y; Hibino S; Ota T; Iguchi M; Okamura T; Gemma A
    Int J Clin Oncol; 2009 Feb; 14(1):63-9. PubMed ID: 19225927
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Prognostic factors and response of chemotherapy including amrubicin in small cell lung cancer patients].
    Wang Y; Liu L; Wu M; Zhong J; Liu X; An T; Zhao J; Duan J; Wang Z; Zhou M; Wang J
    Zhonghua Jie He He Hu Xi Za Zhi; 2015 Apr; 38(4):261-6. PubMed ID: 26268231
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer.
    Naito Y; Yamada K; Imamura Y; Ishii H; Matsuo N; Tokito T; Kinoshita T; Azuma K; Hoshino T
    Med Oncol; 2018 Apr; 35(5):61. PubMed ID: 29610997
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer.
    Shibayama T; Hotta K; Takigawa N; Tada A; Ueoka H; Harita S; Kiura K; Tabata M; Segawa Y; Nogami N; Kuyama S; Shinkai T; Tanimoto M
    Lung Cancer; 2006 Aug; 53(2):189-95. PubMed ID: 16806573
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase I study of weekly doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): A Fred and Pamela Buffet Cancer Center Clinical Trials Network study.
    Ernani V; Jahan R; Smith LM; Marr AS; Kimbrough SE; Kos ME; Tijerina J; Pivovar S; Lakshmanan I; Ketcham M; Rauth S; Mallya K; Nasser MW; Jain M; Kessinger A; Batra SK; Ganti AK
    Cancer Treat Res Commun; 2020; 22():100162. PubMed ID: 31675535
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer.
    Desai A; Smith CJ; Ashara Y; Orme JJ; Zanwar S; Potter A; Hocum C; Moffett JN; Schwecke AJ; Manochakian R; Lou Y; Zhao Y; Ernani V; Savvides P; Molina J; Dimou A; Mansfield AS; Parikh K; Leventakos K
    Clin Lung Cancer; 2023 Dec; 24(8):689-695.e1. PubMed ID: 37880074
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405.
    Inoue A; Ishimoto O; Fukumoto S; Usui K; Suzuki T; Yokouchi H; Maemondo M; Kanbe M; Ogura S; Harada T; Oizumi S; Harada M; Sugawara S; Fukuhara T; Nukiwa T
    Ann Oncol; 2010 Apr; 21(4):800-803. PubMed ID: 19825887
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract: a single cancer center retrospective study.
    Kitagawa Y; Osumi H; Shinozaki E; Ota Y; Nakayama I; Suzuki T; Wakatsuki T; Ichimura T; Ogura M; Ooki A; Takahari D; Suenaga M; Chin K; Yamaguchi K
    Cancer Manag Res; 2019; 11():5757-5764. PubMed ID: 31417315
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Second-line lurbinectedin as a new treatment option for small-cell lung cancer: Preliminary results in real-clinical practice.
    Toublanc AC; Guecamburu M; Veillon R; Rosellini P; Girodet PO; Zysman M
    Thorac Cancer; 2022 Aug; 13(15):2248-2252. PubMed ID: 35715960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.